A COMPANY INSPIRED BY REGENERATION

Transcription

1 OUR FOCUS A COMPANY INSPIRED BY REGENERATION

2 MEET ALLY, a teacher, mother and motorcycle enthusiast with primary biliary cholangitis*(pbc), a rare and potentially fatal non-viral liver disease. OUR FOCUS When I was diagnosed with PBC, my whole world turned upside down. *Formerly known as primary biliary cirrhosis.

3 WE RE HERE FOR YOU, ALLY OUR FOCUS At Intercept, we are inspired by the unique regenerative powers of the liver and are striving to build a healthier tomorrow for patients with non-viral, progressive liver diseases.

4 WHAT IS PBC? Since 1988, PBC has been the second leading overall cause of liver transplants in women in the United States, behind only hepatitis C. 1 PBC is the cause of six percent of all liver transplant cases in Europe. 2 PBC is a rare, potentially fatal, progressive autoimmune disease that causes inflammation and damage to the small bile ducts in the liver. 1 PBC primarily affects women, who are typically diagnosed in the prime of their lives between 35 and 60 years of age. 2 Until recently, only one medicine was available for patients with PBC. In 2016, Intercept introduced the first approved therapy in nearly 20 years to address unmet need in the community. OUR FOCUS 1. Organ Procurement and Transplantation Network. US Health Resources and Services Administration website. Updated May 22, Accessed August 20, Adam et al. Journal of Hepatology September; 57(3): Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol. 2010;52(5): The Disease. Global PBC website. Accessed January 20, 2017.

5 WHAT IS NASH? Nonalcoholic steatohepatitis (NASH) is projected to be the leading cause of liver transplant in the U.S. by NASH is a chronic liver disease caused by excessive fat accumulation and inflammation in the liver, which is unrelated to alcohol consumption. 1 NASH is characterized by progressive fibrosis (scarring) that can lead to cirrhosis, liver failure, cancer and death. 1 OUR FOCUS Since 2001, liver transplants attributed to NASH have increased tenfold in the U.S Chalasani et al. AASLD Practice Guidelines. Hepatology 2012; 55(6): Wree A, et al. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol Nov;10(11): Charlton MR, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011; 141(4):

6 SCIENCE THAT REVOLUTIONIZES At Intercept, we create innovative treatments for non-viral, progressive liver diseases. Using key discoveries we ve made in the field of liver health, we re expanding the applications of our work to solve some of the toughest medical challenges.

7 OUR PIPELINE: LOOKING TO THE FUTURE

8 Rejuvenating tomorrow starts with commitment today. That s why we re partnering with the liver health community. By working together, we develop solutions that improve patients lives and long-term health outcomes. This is Wendy, a mother and music lover who is lliving with PBC. Community Resources We Offer interceptpracticetopolicy.com livingwithpbc.com rethinkpbc.com pbctogether.org COMMITMENT THAT REVITALIZES COMMITMENT THAT REVITALIZES

9 VISION THAT TRANSFORMS In 2002, our company was founded by Mark Pruzanski, M.D., (CEO) with a powerful vision to deliver vital medicines for people living with non-viral, progressive liver diseases. Since then, we ve pioneered a novel scientific platform to develop treatments for patients with unmet need. Looking toward the future, we re working to build on our momentum and revolutionize the way doctors address the liver health community s most pressing needs.

10 THE INTERCEPT STORY Intercept s story dates back nearly 35 years. The company started as a vision in our CEO s small New York City apartment. We ve grown into a biotech firm that is nearly 500 people strong, with one approved product and additional investigational therapies currently in development. Dr. Alan F. Hofmann describes the therapeutic potential of bile acids in a letter to Intercept co-founder, Professor Roberto Pellicciari 1997 HO Researchers describe the role of FXR as a nuclear receptor for bile acids Me Me OH O OH First product approved by FDA/EMA The bile acid UDCA becomes the first medicine approved to treat primary biliary cholangitis (PBC)* 1999 Intercept is founded 2012 Intercept Initial Public Offering *Formerly known as primary biliary cirrhosis.

11 MEET THE TEAM Here at Intercept, our executive leadership is tapping into their unique expertise in liver health and their strong business acumen to develop innovative medicines for non-viral, progressive liver diseases. MARK PRUZANSKI, M.D. Chief Executive Officer & President LISA BRIGHT President of International SANDIP KAPADIA Chief Financial Officer DAVID SHAPIRO, M.D. Chief Medical Officer & Executive Vice President, Development MELISSA REWOLINSKI, PH.D. Senior Vice President of R&D Operations RACHEL MCMINN, PH.D. Chief Business & Strategy Officer JUAN CARLOS LOPEZ-TALAVERA, M.D., PH.D. Senior Vice President of Medical Affairs RICHARD KIM Senior Vice President, Head of US Commercial

12 REVITALIZATION, WORLDWIDE Much like our bold vision for liver health, our headquarters are located in communities where revitalization is underway. Continued growth and corporate presence across the EU, Nordics, Canada and Australia Partnerships with Sumitomo Dainippon Pharmaceuticals in Japan, China and Korea SAN DIEGO, CA, USA Research & Development HQ NEW YORK, NY, USA Corporate & U.S. HQ PERUGIA, ITALY Drug Discovery HQ LONDON, UK International HQ

13 LET S TALK Corporate & U.S. Headquarters 450 W 15th Street Suite 505, Floor 5 New York, NY 10011, US T: F: International Headquarters 2 Pancras Square Kings Cross, London, N1C 4AG, UK T: Research & Development Headquarters 4760 Eastgate Mall San Diego, CA 92121, US T: F: info@interceptpharma.com Custom Address Lorem Ipsum 0000 Fake Address Fake City, XX T: F: INTERCEPT PHARMACEUTICALS, INC. GL-NP-N/A /17